<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Growing interest in universal" exact="influenza" post="vaccines and novel administration routes has led to the"/>
 <result pre="with two variants of the hemagglutinin protein from the A/California/7/2009" exact="influenza" post="virus. The signals detected were assigned to different groups"/>
 <result pre="broadly protective antibodies, especially in the case of novel universal" exact="influenza" post="vaccine approaches. hemagglutinin stalk domain HA2-antibody competitive ELISA universal"/>
 <result pre="influenza vaccine approaches. hemagglutinin stalk domain HA2-antibody competitive ELISA universal" exact="influenza" post="vaccine 1. Introduction Influenza continues to have a significant"/>
 <result pre="effective method of preventing the morbidity and mortality caused by" exact="influenza" post="infection, especially in groups at high risk of dangerous"/>
 <result pre="young children and the elderly [2], although the effectiveness of" exact="influenza" post="vaccination is strictly dependent on the age-group and vaccine"/>
 <result pre="HA antigens. Current inactivated intramuscular/intradermal vaccines (IIVs) or live attenuated" exact="influenza" post="vaccines (LAIVs) are made with a carefully standardized amount"/>
 <result pre="with a carefully standardized amount of HA from three (trivalent" exact="influenza" post="vaccine—TIV) or four (quadrivalent influenza vaccine—QIV) seasonal strains on"/>
 <result pre="of HA from three (trivalent influenza vaccine—TIV) or four (quadrivalent" exact="influenza" post="vaccine—QIV) seasonal strains on the basis of recommendations by"/>
 <result pre="Another important consideration is the fact that the currently available" exact="influenza" post="vaccines are not able to protect against emerging pandemic-like"/>
 <result pre="influenza vaccines are not able to protect against emerging pandemic-like" exact="influenza" post="viruses [11]. Moreover, with today’s manufacturing technologies, it would"/>
 <result pre="the 2009 H1N1 pandemic [12,13]. The development of a universal" exact="influenza" post="vaccine would avoid potential mismatches of recommended vaccine strains"/>
 <result pre="a pandemic, and it might result in the eradication of" exact="influenza" post="B virus in humans. Several candidate target antigens could"/>
 <result pre="candidate target antigens could be considered for use in universal" exact="influenza" post="vaccines, such as the M2 ion channel [14], NA"/>
 <result pre="domain is the most conserved region of HA in the" exact="influenza" post="A and B viruses. Its main function is to"/>
 <result pre="process are not permitted [17]. Classically, antibody-mediated immune responses after" exact="influenza" post="vaccination or natural infection are assessed by standard serological"/>
 <result pre="region of HA, which are conserved among different subtypes of" exact="influenza" post="A viruses. The SRH assay may recognize not only"/>
 <result pre="obese subjects [23]. The growing interest in developing a universal" exact="influenza" post="vaccine has led to the need for alternative serological"/>
 <result pre="antibodies against conserved epitopes among group 1 and group 2" exact="influenza" post="A viruses by measuring the difference between the HA"/>
 <result pre="and Methods 2.1. Virus Antigen The virus antigen and infectious" exact="influenza" post="virus was the seasonal influenza strain A/California/7/2009 H1N1 (15/252),"/>
 <result pre="The virus antigen and infectious influenza virus was the seasonal" exact="influenza" post="strain A/California/7/2009 H1N1 (15/252), grown in eggs and obtained"/>
 <result pre="run in the HI assay by using the A/California/7/2009 H1N1pdm09" exact="influenza" post="strain, as described elsewhere [31]. HI titers below 10"/>
 <result pre="humidified atmosphere with a standardized amount of live A/California/7/2009 H1N1" exact="influenza" post="virus (100 tissue culture infective dose 50% (TCID50)). After"/>
 <result pre="diluted serum samples were mixed with a standardized amount of" exact="influenza" post="pseudotypes bearing N1 from A/California/7/2009, and incubated for 16–18"/>
 <result pre="18–529) and head (aa 18–345) proteins from the A/California/7/2009 H1N1" exact="influenza" post="virus (eEnzyme, Gaithersburg, MD, USA). A solution of 5%"/>
 <result pre="generally used in order to evaluate the immunogenicity of an" exact="influenza" post="vaccine (MN, SRH and ELLA), along with the competitive"/>
 <result pre="unsatisfactory [35], one of the main drawbacks of the current" exact="influenza" post="vaccines is the need for an annual reformulation and"/>
 <result pre="consequent global re-administration, owing to the antigenic drift of the" exact="influenza" post="virus. In the last two decades, growing interest in"/>
 <result pre="of developing a universal vaccine has given new impetus to" exact="influenza" post="research. Several studies have focused on the extracellular domain"/>
 <result pre="sequence has proven to be highly conserved among human and" exact="avian influenza" post="viruses. However, antibodies that are elicited against this conserved"/>
 <result pre="has proven to be highly conserved among human and avian" exact="influenza" post="viruses. However, antibodies that are elicited against this conserved"/>
 <result pre="abundant glycoprotein that is present on the surface of the" exact="influenza" post="virus, is another important target. Previous murine studies that"/>
 <result pre="carried out with a view to developing a stalk-based universal" exact="influenza" post="vaccine; this research has mainly been based on a"/>
 <result pre="and nasal turbinates in mice and ferrets [16]. A universal" exact="influenza" post="vaccine that is able to stimulate stalk-specific antibodies has"/>
 <result pre="strains; moreover, it would confer greater protection against new emerging" exact="influenza" post="viruses, particularly those that pose a pandemic threat [41]."/>
 <result pre="antibodies. Nevertheless, it can support studies of the immunogenicity of" exact="influenza" post="vaccines by detecting and quantifying specific immune responses against"/>
 <result pre="study of the immune responses that are induced by next-generation" exact="influenza" post="vaccines, such as those based on conserved epitopes from"/>
 <result pre="least some of them of being completely naïve for A/H1N1/California/7/2009" exact="influenza" post="strain at the time of blood draw. The high"/>
 <result pre="difficult to be elicited by classical inactivated split and subunit" exact="influenza" post="vaccines [50]; and 3) the influenza specific B- (and"/>
 <result pre="inactivated split and subunit influenza vaccines [50]; and 3) the" exact="influenza" post="specific B- (and T-) cells repertoires in young children"/>
 <result pre="NA responses. The unpredictability and complexity of immune responses against" exact="influenza" post="vaccination are illustrated by the fact that this subject"/>
 <result pre="large number of antibodies directed against conserved epitopes of the" exact="influenza" post="virus, thus causing the steric hindrance of the hemagglutination"/>
 <result pre="and NA, it may also reflect the fact that internal" exact="influenza" post="virus proteins may be involved in the complement fixation"/>
 <result pre="by multiple assays for the evaluation of the effectiveness of" exact="influenza" post="vaccines. In the present study, we also included the"/>
 <result pre="However, it is important to point out that current licensed" exact="influenza" post="vaccines are made with a well standardized amount of"/>
 <result pre="responses, thereby allowing the mode of action of different (next-generation)" exact="influenza" post="vaccine approaches to be interpreted. Specifically, as reported in"/>
 <result pre="generally used to evaluate the immunogenicity of HA-based intramuscular/intradermal seasonal" exact="influenza" post="vaccines are still valid. However, they could be insufficient"/>
 <result pre="insufficient in the evaluation of the immune response of next-generation" exact="influenza" post="vaccines, especially if used alone. This preliminary study presents"/>
 <result pre="the use of HA and head subunits from a single" exact="influenza" post="strain. Further studies will be done with the aim"/>
 <result pre="on Immunization Practices (ACIP), 2007MMWR Recomm. Rep.20075615417625497 3.GoodwinK.ViboudC.SimonsenL.Antibody response to" exact="influenza" post="vaccination in the elderly: A quantitative reviewVaccine2006241159116910.1016/j.vaccine.2005.08.10516213065 4.FrascaD.DiazA.RomeroM.MendezN.V.LandinA.M.BlombergB.B.Effects of"/>
 <result pre="H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011–2012" exact="influenza" post="vaccine seasonImmun. Ageing2013101410.1186/1742-4933-10-1423607926 5.KatzJ.M.HancockK.XuX.Serologic assays for influenza surveillance, diagnosis"/>
 <result pre="during the 2011–2012 influenza vaccine seasonImmun. Ageing2013101410.1186/1742-4933-10-1423607926 5.KatzJ.M.HancockK.XuX.Serologic assays for" exact="influenza" post="surveillance, diagnosis and vaccine evaluationExpert Rev. Anti-infective Ther.2011966968310.1586/eri.11.51 6.FinkenstädtB.F.MortonA.RandD.A.Modelling"/>
 <result pre="Viruses Using biophysical ideasSci. Rep.201991021810.1038/s41598-019-46740-531308446 10.De JongJ.C.BeyerW.E.PalacheA.M.RimmelzwaanG.F.OsterhausA.D.Mismatch between the 1997/1998" exact="influenza" post="vaccine and the major epidemic A(H3N2) virus strain as"/>
 <result pre="development of egg-independent vaccines for influenzaExpert Rev. Vaccines20191873775010.1080/14760584.2019.163950331265333 14.NeirynckS.DeRooT.SaelensX.VanlandschootP.JouW.M.FiersW.A universal" exact="influenza" post="A vaccine based on the extracellular domain of the"/>
 <result pre="16.ThompsonC.P.LourençoJ.WaltersA.A.ObolskiU.EdmansM.PalmerD.S.KooblallK.CarnellG.W.O’ConnorD.BowdenT.A.et al.A naturally protective epitope of limited variability as an" exact="influenza" post="vaccine targetNat. Commun.20189385910.1038/s41467-018-06228-830242149 17.KrammerF.PaleseP.Influenza virus hemagglutinin stalk-based antibodies and"/>
 <result pre="neutralization assays, and ELISA to detect antibody levels against seasonal" exact="influenza" post="virusesInflu. Other Respir. Viruses20181267568610.1111/irv.12591 21.BlackS.NicolayU.VesikariT.KnufM.Del GiudiceG.Della CioppaG.TsaiT.ClemensR.RappuoliR.Hemagglutination Inhibition Antibody"/>
 <result pre="in ChildrenPediatr. Infect. Dis. J.2011301081108510.1097/INF.0b013e318236766221983214 22.ShahidZ.KleppingerA.GentlemanB.FalseyA.R.McElhaneyJ.E.Clinical and immunologic predictors of" exact="influenza" post="illness among vaccinated older adultsVaccine2010286145615110.1016/j.vaccine.2010.07.03620646987 23.NeidichS.D.GreenW.D.RebelesJ.KarlssonE.A.Schultz-CherryS.NoahT.L.ChakladarS.HudgensM.G.WeirS.S.BeckM.A.Increased risk of influenza"/>
 <result pre="of influenza illness among vaccinated older adultsVaccine2010286145615110.1016/j.vaccine.2010.07.03620646987 23.NeidichS.D.GreenW.D.RebelesJ.KarlssonE.A.Schultz-CherryS.NoahT.L.ChakladarS.HudgensM.G.WeirS.S.BeckM.A.Increased risk of" exact="influenza" post="among vaccinated adults who are obeseInt. J. Obes.2017411324133010.1038/ijo.2017.131 24.GianchecchiE.ManentiA.KistnerO.TrombettaC.ManiniI.MontomoliE.How"/>
 <result pre="obeseInt. J. Obes.2017411324133010.1038/ijo.2017.131 24.GianchecchiE.ManentiA.KistnerO.TrombettaC.ManiniI.MontomoliE.How to assess the effectiveness of nasal" exact="influenza" post="vaccines? Role and measurement of sIgA in mucosal secretionsInflu."/>
 <result pre="Protection in a Serum Transfer Mouse Challenge ModelmBio20178e01463-1710.1128/mBio.01463-1728928215 27.GravesP.SchulmanJ.YoungJ.PaleseP.Preparation of" exact="influenza" post="virus subviral particles lacking the HA1 subunit of hemagglutinin:"/>
 <result pre="HA2 determinantsVirology198312610611610.1016/0042-6822(83)90465-86189287 28.SagawaH.OhshimaA.KatoI.OkunoY.IsegawaY.The immunological activity of a deletion mutant of" exact="influenza" post="virus haemagglutinin lacking the globular regionJ. Gen. Virol.1996771483148710.1099/0022-1317-77-7-14838757990 29.WohlboldT.J.NachbagauerR.MargineI.TanG.S.HirshA.KrammerF.Vaccination"/>
 <result pre="with soluble headless hemagglutinin protects mice from challenge with divergent" exact="influenza" post="virusesVaccine2015333314332110.1016/j.vaccine.2015.05.03826026378 30.BiusoF.CarnellG.W.MontomoliE.TempertonN.A Lentiviral Pseudotype ELLA for the Measurement of"/>
 <result pre="Radial Hemolysis assay: A reliable method to measure antibodies against" exact="influenza" post="virusesJ. Immunol. Methods20154229510110.1016/j.jim.2015.04.00925910832 33.AinaiA.TamuraS.-I.SuzukiT.Van RietE.ItoR.OdagiriT.TashiroM.KurataT.HasegawaH.Intranasal vaccination with an inactivated"/>
 <result pre="virusesJ. Immunol. Methods20154229510110.1016/j.jim.2015.04.00925910832 33.AinaiA.TamuraS.-I.SuzukiT.Van RietE.ItoR.OdagiriT.TashiroM.KurataT.HasegawaH.Intranasal vaccination with an inactivated whole" exact="influenza" post="virus vaccine induces strong antibody responses in serum and"/>
 <result pre="adultsHum. Vaccines Immunother.201391962197010.4161/hv.2545823896606 34.CouzensL.GaoJ.WestgeestK.SandbulteM.LugovtsevV.FouchierR.EichelbergerM.An optimized enzyme-linked lectin assay to measure" exact="influenza" post="A virus neuraminidase inhibition antibody titers in human seraJ."/>
 <result pre="Methods201421071410.1016/j.jviromet.2014.09.00325233882 35.collab: Centers for Disease Control and PreventionInterim results: State-specific" exact="influenza" post="vaccination coverage—United States, August 2010–February 2011MMWR. Morb. Mortal. Wkly."/>
 <result pre="Virol.1988622762277210.1128/JVI.62.8.2762-2772.19882455818 37.TreanorJ.J.TierneyE.L.ZebedeeS.L.LambR.A.MurphyB.R.Passively transferred monoclonal antibody to the M2 protein inhibits" exact="influenza" post="A virus replication in miceJ. Virol.1990641375137710.1128/JVI.64.3.1375-1377.19902304147 38.LeeY.-N.LeeY.-T.KimM.-C.HwangH.S.LeeJ.S.KimK.-H.KangS.-M.Fc receptor is"/>
 <result pre="antibodies but plays a critical role in conferring protection after" exact="influenza" post="M2 vaccinationImmunol.201414330030910.1111/imm.1231024773389 39.QuanF.-S.KimM.-C.LeeB.-J.SongJ.-M.CompansR.W.KangS.-M.Influenza M1 VLPs containing neuraminidase induce heterosubtypic"/>
 <result pre="cross-protectionVirol.201243012713510.1016/j.virol.2012.05.006 40.OkunoY.IsegawaY.SasaoF.UedaS.A common neutralizing epitope conserved between the hemagglutinins of" exact="influenza" post="A virus H1 and H2 strainsJ. Virol.1993672552255810.1128/JVI.67.5.2552-2558.19937682624 41.KrammerF.PaleseP.Universal influenza"/>
 <result pre="of influenza A virus H1 and H2 strainsJ. Virol.1993672552255810.1128/JVI.67.5.2552-2558.19937682624 41.KrammerF.PaleseP.Universal" exact="influenza" post="virus vaccines: Need for clinical trialsNat. Immunol.2014153510.1038/ni.276124352315 42.BommakantiG.CitronM.P.HeplerR.W.CallahanC.HeideckerG.J.NajarT.A.LuX.JoyceJ.G.ShiverJ.W.CasimiroD.R.et al.Design"/>
 <result pre="trialsNat. Immunol.2014153510.1038/ni.276124352315 42.BommakantiG.CitronM.P.HeplerR.W.CallahanC.HeideckerG.J.NajarT.A.LuX.JoyceJ.G.ShiverJ.W.CasimiroD.R.et al.Design of an HA2-based Escherichia coli expressed" exact="influenza" post="immunogen that protects mice from pathogenic challengeProc. Natl. Acad."/>
 <result pre="on Influenza VaccinesEuropean Medicine AgencyAmsterdam, The Netherlands2016size: 31ppages 46.WoodJ.Gaines-DasR.TaylorJ.ChakravertyP.Comparison of" exact="influenza" post="serological techniques by international collaborative studyVaccine19941216717410.1016/0264-410X(94)90056-68147099 47.Van DammeP.ArnouR.KafejaF.FiquetA.RichardP.ThomasS.MeghlaouiG.SamsonS.I.LedesmaE.Evaluation of"/>
 <result pre="studyVaccine19941216717410.1016/0264-410X(94)90056-68147099 47.Van DammeP.ArnouR.KafejaF.FiquetA.RichardP.ThomasS.MeghlaouiG.SamsonS.I.LedesmaE.Evaluation of non-inferiority of intradermal versus adjuvanted seasonal" exact="influenza" post="vaccine using two serological techniques: A randomised comparative studyBMC"/>
 <result pre="haemagglutinin inhibition and microneutralization as a correlate of protection against" exact="influenza" post="A H3N2 in children and adolescentsInflu. Other Respir. Viruses20171128328810.1111/irv.1245028218983"/>
 <result pre="Perspect. Med.201910.1101/cshperspect.a038430 52.LiY.MyersJ.L.BostickD.L.SullivanC.B.MadaraJ.LindermanS.L.LiuQ.CarterD.M.WrammertJ.EspositoS.et al.Immune history shapes specificity of pandemic H1N1" exact="influenza" post="antibody responsesJ. Exp. Med.20132101493150010.1084/jem.2013021223857983 53.LeonP.E.HeW.MullarkeyC.E.BaileyM.J.MillerM.S.KrammerF.PaleseP.TanG.S.Optimal activation of Fc-mediated effector"/>
 <result pre="responsesJ. Exp. Med.20132101493150010.1084/jem.2013021223857983 53.LeonP.E.HeW.MullarkeyC.E.BaileyM.J.MillerM.S.KrammerF.PaleseP.TanG.S.Optimal activation of Fc-mediated effector functions by" exact="influenza" post="virus hemagglutinin antibodies requires two points of contactProc. Natl."/>
 <result pre="with a purified hemagglutinin (HA) recombinant protein from A/California/7/2009 (H1N1)" exact="influenza" post="strain. (B) A 1:250 pre-diluted serum sample is treated"/>
</results>
